Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Validation of an AI-enabled clinical trial matching solution in cancer patients

Jai Patel, PharmD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, presents expert validation of a novel artificial intelligence (AI)-enabled system using large language model-based decision rules and electronic health records to match patients with cancer to clinical trials. Results demonstrated high sensitivity, specificity, and strong criterion-level agreement with expert clinical research coordinator adjudication, with the system identifying potential missed enrollment opportunities, This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

This is really a spinoff through a program called CancerX, where we’re co-developing this AI platform with another company called LendAI, a startup company. And during this co-development process, really the first phase of this is to validate that platform using real-world data from our own patient records, as well as real cancer trial protocols. And this has really been one of the gaps in prior literature that have mostly focused on synthetic data sets...

This is really a spinoff through a program called CancerX, where we’re co-developing this AI platform with another company called LendAI, a startup company. And during this co-development process, really the first phase of this is to validate that platform using real-world data from our own patient records, as well as real cancer trial protocols. And this has really been one of the gaps in prior literature that have mostly focused on synthetic data sets. So we took an opportunity to take thousands of patients within our own health system, develop the model, train the model, use machine learning plus large language models, kind of a hybrid architecture to further train that model and then test it in a separate independent test set of patients. So the test set of patients focused on individuals with breast cancer, lung cancer, and pancreatic cancer. So we were matching these patients to retrospective clinical trial protocols. In that study, we identified that there was actually 94% agreement or concordance between a clinical research coordinator reviewing the data versus the AI platform, so performing really just as well as the human review. So at different probability thresholds, we then determined that the platform can have upwards of 99% sensitivity and positive predictive performance really upwards of, again, 90% or so, meaning that every nine out of every 10 patients or so that the AI platform says the individual is eligible for the clinical trial, they truly end up being eligible for that particular clinical trial.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...